Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.
Saved in:
| Title: | Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study. |
|---|---|
| Authors: | Klein-Scory S; Department of Internal Medicine, Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH, Ruhr University Bochum, Germany., Baraniskin A; Department of Internal Medicine, Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH, Ruhr University Bochum, Germany.; Department of Hematology, Oncology and Palliative Care, Evangelisches Krankenhaus Hamm gGmbH, Germany., Schmiegel W; Department of Internal Medicine, Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH, Ruhr University Bochum, Germany., Mika T; Department of Internal Medicine, Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH, Ruhr University Bochum, Germany., Schroers R; Department of Internal Medicine, Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH, Ruhr University Bochum, Germany., Held S; ClinAssess GmbH, Leverkusen, Germany., Heinrich K; Department of Oncology, LMU University Hospital, Munich, Germany., Tougeron D; Department of Hepato-Gastroenterology, Poitiers University Hospital and University of Poitiers, France., Modest DP; Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité-Universitaetsmedizin Berlin, Germany., Schwaner I; Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany., Eucker J; Department of Hematology, Oncology, and Cancer Immunology (CBF), Charité-Universitaetsmedizin Berlin, Germany., Pihusch R; MVZ Praxis Pihusch, Rosenheim, Germany., Stauch M; Hematology, Oncology/Hemostaseology Kronach, Germany., Kaiser F; VK&K Studien GmbH, Landshut, Germany., Kahl C; Klinikum Magdeburg gGmbH, Department of Hematology, Oncology and Palliative Care Magdeburg, Germany.; Department of Internal Medicine, Clinic III - Hematology, Oncology and Palliative Care, Rostock University Medical Center, Germany., Karthaus M; Department of Hematology, Oncology and Palliative Care, München Klinik Harlaching and Neuperlach, Germany., Müller C; Evang. Kliniken Essen-Mitte, Germany., Burkart C; Schwarzwald-Baar Klinikum Villingen-Schwenningen, Germany., Stintzing S; Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité-Universitaetsmedizin Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Site Berlin Heidelberg, Germany., Heinemann V; Department of Medicine III, LMU Klinikum, Comprehensive Cancer Center Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Site Munich Heidelberg, Germany. |
| Source: | Molecular oncology [Mol Oncol] 2025 Feb; Vol. 19 (2), pp. 344-356. Date of Electronic Publication: 2024 Dec 04. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.13778 |
